Pharmacology and practice of opioid drugs for visceral pain

Chronic Abdominal and Visceral Pain: Theory and Practice

Volumn , Issue , 2006, Pages 287-299

  Ballantyne, Jane C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85052581818     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (83)

1. Porter J, Jick H. Addiction rare in patients treated with narcotics (letter). N Engl J Med 1980; 302.
2. Drossman DA. Gastrointestinal illness and the biopsychosocial model. Psychos Med 1998; 60:258.
3. Dersh J, Polatin PB, Gatchell RJ. Chronic pain and psychopathology: research finding and theoretical considerations. Psychom Med 2002; 64:773.
4. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63:649.
5. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Neuropharmacol 1993; 16:1.
6. Greenwald MK, Stitzer ML, Haberny KA. Human pharmacology of the opioid neuropeptide dynorphine. 1997; 281:1154.
7. Rang HP, Dale MM, Ritter JM. Analgesic drugs. In: Rang HP, ed. Pharmacology. 4th Ed., New York: Churchill Livingstone; 1999: 579.
8. De Schepper HU, et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16:383.
9. Huse E et al. The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001; 90:47.
10. Attal NA et al. Effects of IV morphine in central pain. A randomized placebo-controlled study. Neurology 2002; 58:554.
11. Caldwell JR et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002; 23:278.
12. Watson CPN et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105:71.
13. Fishman SM et al. Methadone reincarnated: novel clinical applications with related concerns. Pain Med 2002; 3:339.
14. Wilson PR. ASA statement to FDA committee. Opioid use and diversion: report on recent hearing by FDA and DEA. ASA Newslett 2002; 66:9.
15. Ballantyne JC, Mao J. Opioids for chronic pain. N Engl J Med 2003; 349:1943.
16. DeHaven-Hudkins DL, Dolle RE. Peripherally restricted opioid agonists as novel analgesic agents. Curr Pharma Des 2004; 10:743.
17. Hanks GW, Forbes K. Opioid responsiveness. Acta Anaesth Scand 1997; 41:154.
18. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41:1024.
19. Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997; 349:753.
20. Rowbotham MD et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348:1223.
21. Foley KM. Opioids and chronic neuropathic pain. N Engl J Med 2003; 348:1278-1281.
22. Thompson DR. Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol 2001; 96:1266.
23. Wilder-Smith CH et al. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Digest Dis Sci 1999; 44:1107.
24. Lee F, Cundiff D. Meperidine vs. morphine in pancreatitis and cholecystitis. Arch Intern Med 1998; 158:2399.
25. Niemann T et al. Opioid treatment of painful chronic pancreatitis. Intern J Pancreatol 2000; 27:235.
26. Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 2002; 35:S58.
27. Mach T. The brain-gut axis in irritable bowel syndrome-clinical aspects Med Sci Monitor 2004; 10:RA125.
28. Cervero F. Visceral pain-central sensitization. Gut 2000; 47(suppl 4):iv56-iv57; discussion iv58.
29. Whitehead WE, Engle BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980; 25.
30. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107:271.
31. Gebhart GF. Visceral pain-peripheral sensitization Gut 2000; 47:(suppl 4):iv54-iv56; discussion iv58.
32. Gebhart GF. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications IV. Visceral afferent contributions to the pathobiology of visceral pain. Am J Physiol Gastrointest Liver Physiol 2000; 278:G834.
33. Black D, Trevethick M. The kappa opioid receptor is associated with the perception of visceral pain. Gut 1998; 43:312.
34. Simonin F et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 1998; 17:886.
35. Su X, Wachtel RE, Gebhart GF. Inhibition of calcium currents in rat colon sensory neurons by κ- but not mu- or delta-opioids. J Neurophysiol 1998; 80:3112.
36. Gebhart GF et al. Peripheral opioid modulation of visceral pain. Ann N Y Acad Sci 2000; 909:41.
37. Su X et al. Sodium channel blocking actions of the kappa-opioid receptor agonist U50, 488 contribute to its visceral antinociceptive effects J Neurophysiol 2002; 87:1271.
38. Blackshaw LA, Gebhart GF. The pharmacology of gastrointestinal nociceptive pathways. Curr Opin Pharmacol 2002; 2:642.
39. Martin TJ, Eisenach JC. Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther 2001; 299:811.
40. Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 2003; 101:89.
41. Ballantyne JC et al. Postoperative patient-controlled analgesia: meta-analyses of initial randomized control trials. J Clin Anesth 1993; 5:182.
42. Walder B et al. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain: a quantitative systematic review. Acta Anaesth Scand 2001; 45:795.
43. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11:203.
44. West JE et al. Model guidelines for the use of controlled substances for the treatment of pain. A policy document of the Federation of State Medical Boards of the United States Inc, 1998.
45. Haddox JD et al. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. American Academy of Pain Medicine and American Pain Society, 1997.
46. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986; 25:171.
47. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and opiate tolerance: a current view of their possible interactions. Pain 1995; 62:259-274.
48. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301.
49. Mao J. Opioid induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002; 100:213.
50. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther 1975; 192:211.
51. Mendelson JH et al. Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther 1975; 195:296.
52. Abs R et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metabol 2000; 85:2215.
53. Finch PM et al. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000; 16:251.
54. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3:377.
55. Daniell HW. Narcotic-induced hypogonadism during therapy for heroin addiction. J Addict Dis 2002; 21:47.
56. Bliesener N et al. Plasma testosterone and sexual function in men on buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 2004.
57. Daniell HW. The association of endogenous hormone levels and exogenously administered opiates in males. Am J Pain Manage 2001; 11:8.
58. Rajagopal A et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004; 100:851.
59. Rajagopal A et al. Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage 2003; 26:1055.
60. Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res 1996; 21:1375.
61. Risdahl JM et al. Opiates and infection. J Neuroimmunol 1998; 83:4.
62. Makman MH. Morphine receptors in immunocytes and neurons. Adv Neuroimmunol 1994; 4:69.
63. Rahim RT et al. Abrupt or precipitated withdrawal from morphine induces immunosuppression. J Neuroimmunol 2002; 127:88.
64. Philippe D et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 2003; 111:1329.
65. Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349:975.
66. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
67. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence and addiction in chronic pain patients. Clin J Pain 1992; 8:77.
68. Passik SD et al. A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage 2000; 19:274.
69. Adams LL et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage 2004; 27:440.
70. Butler SF et al. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004; 112:65.
71. Wilsey BL, Fishman SM. Chronic opioid therapy, drug abuse and addiction. MGH Handbook of Pain Management. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins, 2006: 513.
72. Savage S et al. Definitions related to the use of opioids for the treatment of pain. A Consensus Document from the American Academy of Pain Medicine. American Pain Society and the American Society of Addiction Medicine. 2001.
73. National Institute of Drug Abuse (NIDA), Info Facts, Prescription drugs and pain medications 1999. http://nida.nih.gov/Infofax/PainMed.html/http://www.gov/ResearchReports/Prescription7html.
74. CASA Report: missed opportunity. National survey of primary care physicians on patients with substance abuse. New York: National Center on Addiction and Substance Abuse. Columbia University, 2000.
75. DHHS, SAMHSA. National Household Survey on Drug Abuse Main Findings. Series H-11, 1998.
76. Karram MM. The painful bladder: urethral syndrome and interstitial cystitis. Curr Opin Obstet Gynecol 1990; 2:605.
77. Longstreth GF. Irritable bowel syndrome and chronic pelvic pain. Obstet Gynecol Survey 1994; 49:505.
78. Ghaly AFF, Chien PFW. Chronic pelvic pain: clinical dilemma of clinician's nightmare. Sex Transmit Infect 2000; 76:419.
79. Warshaw AL, Banks PA, Fernandez-Del Castillo C. AGA technical review: treatment of pain in chronic pancreatitis. Gastroenterology1998; 115:765.
80. Compton P, Darakjian J, Miotto K. Screening for addiction in patients with chronic pain with "problematic" substance use: evaluation of a pilot assessment tool. J Pain Symptom Manage 1998; 16:355.
81. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA 2000; 284:1383.
82. Mercadante S. Opioid rotation for cancer pain. Cancer 1999; 86:1856.
83. Pasternak GW. The pharmacology of mu analgesics: from patients to genes. Neuroscientist 2001; 7:220.